HX GROUP(SH:900917)2023-04-27 16:00Financial Performance - In 2022, the company achieved a net profit attributable to shareholders of RMB 164,056,061.10, representing a 24.20% increase compared to RMB 132,091,780.53 in 2021[6]. - The company's operating revenue for 2022 was RMB 1,440,090,739.79, a decrease of 4.71% from RMB 1,511,255,284.73 in 2021[23]. - The net cash flow from operating activities decreased by 66.51% to RMB 73,558,233.78, down from RMB 219,647,104.26 in the previous year[23]. - The basic earnings per share for 2022 increased by 24.22% to RMB 0.1359, compared to RMB 0.1094 in 2021[25]. - The company reported a significant increase in net profit after deducting non-recurring gains and losses, which rose by 50.03% to RMB 155,822,289.93[23]. - The company achieved a consolidated revenue of CNY 1.44 billion in 2022, a decrease of 4.71% year-on-year[45]. - The net profit attributable to the parent company was CNY 164 million, an increase of 24.20% year-on-year[45]. - Total revenue for the year was approximately CNY 1,277.75 million, a decrease of 5.92% compared to the previous year[50]. Asset Management - The company's total assets as of the end of 2022 were RMB 4,930,064,090.03, a decrease of 7.43% from RMB 5,325,619,470.52 at the end of 2021[23]. - The company’s net assets attributable to shareholders decreased by 6.90% to RMB 3,843,579,153.36 at the end of 2022, down from RMB 4,128,288,109.68 at the end of 2021[23]. - The total assets at the end of 2022 were CNY 4.93 billion, a decrease of 7.43% primarily due to a decline in the market value of holdings in Changjiang Securities[45]. - The company disposed of inefficient assets to improve overall asset quality, establishing a dedicated asset disposal task force[39]. - The company’s long-term equity investments increased to RMB 1,127.03 million in 2022, compared to RMB 1,080.90 million in 2021, marking an increase of about 4.3%[194]. Segment Performance - The pharmaceutical segment reported a consolidated operating revenue of 801.98 million RMB, down 8.13% year-on-year, with a net profit of 19.09 million RMB, up 35.12%[33]. - The property segment generated rental income of 75.43 million RMB, an increase of 5.32% year-on-year, and operating net profit of 49.11 million RMB, up 21.32%[35]. - The textile segment reported operating revenue of 231.94 million RMB, an increase of 13.31% year-on-year, but incurred a net loss of 9.03 million RMB due to restructuring costs[36]. - The company reported a net cash flow from operating activities of 33.56 million RMB in Q4 2022, indicating improved cash generation capabilities[27]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of RMB 0.45 per 10 shares, totaling RMB 54,317,551.14, which accounts for 33.11% of the net profit attributable to shareholders[6]. - The cash dividend per 10 shares is CNY 0.45, with no stock dividends or capital increases proposed[123]. - The company declared a cash dividend of CNY 54,317,551.14, which represents 33.11% of the net profit attributable to ordinary shareholders in the consolidated financial statements[123]. Risk Management - The company highlighted risks related to future development strategies and operational plans, advising investors to be cautious[9]. - The company faces market risks due to intense competition in its pharmaceutical and textile businesses, which could significantly impact performance[77]. - Regulatory risks from stricter environmental policies and changes in healthcare and real estate regulations may affect the company's operations[78]. Corporate Governance - The board of directors consists of 9 members, including 3 independent directors, complying with legal requirements[85]. - The supervisory board is composed of 2 supervisors and 1 employee supervisor, adhering to legal standards[86]. - The company has established a performance evaluation and incentive mechanism linking senior management compensation to company and individual performance[87]. - The company has implemented an information disclosure management system to ensure timely and accurate information dissemination to shareholders[88]. Environmental Compliance - The company has implemented effective measures to ensure that all emissions are within the regulatory limits, demonstrating commitment to environmental compliance[135]. - The company has a wastewater treatment station with a daily capacity of 1,500 tons, which discharges treated water to an industrial wastewater treatment plant for further processing before discharge[140]. - The company reported no administrative penalties for environmental issues during the reporting period[144]. Future Outlook - Future outlook indicates a projected revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies[96]. - The company is investing in R&D for new technologies, with an allocated budget of $50 million for the upcoming year[96]. - Market expansion plans include entering three new international markets by the end of 2024, aiming for a 10% market share in each[96].